For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Vilon (Lys-Glu) is the smallest member of the Khavinson bioregulator family: a synthetic dipeptide derived from thymic tissue designed to reactivate age-silenced gene expression. Its in vitro chromatin remodeling data in human aged lymphocytes are mechanistically compelling, and the CBA mouse longevity findings span two decades. The HER-2/neu pro-tumorigenic finding in the same research program is a safety signal most vendor content omits entirely. No human clinical trials have been published after four decades of animal research.
Vilon is a research compound with no FDA or EMA approval, no completed controlled human clinical trials, and no published human pharmacokinetic data for any route. All findings discussed in this profile are from rodent in vivo experiments or in vitro cell culture work, including studies using human lymphocytes. Cell culture experiments with human material are not equivalent to clinical trials.
There is a preclinical safety signal that most commercial Vilon content omits: two published studies from the same group responsible for Vilon's geroprotective data showed that Vilon increased mammary tumor incidence, shortened tumor latency, and increased cumulative tumor number in HER-2/neu transgenic mice (Anisimov et al., International Journal of Cancer, 2002; Alimova et al., Advances in Gerontology, 2003). Epitalon produced the opposite effect in the same experiments. This finding does not establish human cancer risk, but it is a formal preclinical red flag. Individuals with known or suspected HER-2-positive malignancy or strong family history of HER-2-positive breast cancer should treat this as a contraindication until prospective data exist.
Virtually all published Vilon research originates from Professor Vladimir Khavinson's laboratory at the St. Petersburg Institute of Bioregulation and Gerontology. Independent external replication of core findings was essentially absent until the 2022 THP-1 macrophage study by Italian institutions (IJMS, Iannone et al.), which confirmed intracellular signaling effects but did not address clinical outcomes. The concentration of the evidence base within one institution over four decades, without progression to human trials, is a notable feature of this compound's development history.
Vilon is a synthetic dipeptide composed of L-lysine and L-glutamic acid (Lys-Glu), developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology beginning in the late 1970s. It is the smallest compound in the Khavinson bioregulator family and is described by that group as the shortest peptide sequence known to exhibit measurable tissue-specific biological activity.
The compound was built using directed amino acid synthesis: quantitative analysis of Thymalin, a natural thymus extract that had already demonstrated immunomodulatory properties in Soviet-era clinical use, identified lysine and glutamic acid as its most abundant amino acids. Khavinson's team synthesized this minimal Lys-Glu sequence as a candidate active fraction. The same logic applied to produce other family members: Thymogen (Glu-Trp, also from thymic analysis), Epithalon (Ala-Glu-Asp-Gly, from pineal), and Cortagen (Ala-Glu-Asp-Pro, from brain cortex).
The thymus was chosen as the source tissue because of its central role in adaptive immunity. The thymus matures T-lymphocytes during youth and undergoes progressive involution with age, producing fewer and less diverse T-cells and driving the immune decline known as immunosenescence. The hypothesis motivating Vilon is that exogenous administration of thymus-derived regulatory peptides can partially restore the gene expression patterns necessary for sustained immune function in aging tissue.
Vilon and its companion compounds have been studied predominantly in Russian and former-Soviet scientific institutions across five decades, with most publications appearing in Bulletin of Experimental Biology and Medicine, Advances in Gerontology, and Biogerontology. This institutional concentration and language of origin has limited uptake of the research in Western medicine, though several key studies were co-authored with Italian and Georgian collaborators.
Vilon's proposed primary mechanism is facultative heterochromatin deheterochromatinization: the reversal of age-associated gene silencing through loosening of compacted chromatin. With aging, genomic regions that were once transcriptionally active compact into heterochromatin structures, reducing expression of proteins involved in immune function, cellular maintenance, and ribosomal activity. Khavinson's group proposes that Vilon, by virtue of its charged dipeptide chemistry, interacts directly with DNA and chromatin proteins to partially reverse this compaction.
The structural rationale has biochemical plausibility. L-lysine carries a positively charged epsilon-amino group at physiological pH, which is attracted to the negatively charged phosphate backbone of DNA. L-glutamic acid carries a negative charge that can interact with positively charged histone proteins that compact chromatin. The Lys-Glu pairing may therefore allow the dipeptide to dock at chromatin interfaces in a way that displaces or repositions nucleosomal proteins, increasing transcription factor accessibility to previously silenced promoters.
The most direct test of this mechanism in human material is the 2004 Biogerontology study by Lezhava et al. Lymphocytes from elderly donors were cultured with Vilon in vitro. Vilon produced: (a) induction of total heterochromatin unrolling; (b) reactivation of ribosomal gene expression via decondensation of nucleolus organizer regions; (c) release of genes previously silenced in facultative heterochromatin; and (d) no decondensation of pericentromeric structural heterochromatin. The last point distinguishes Vilon from Epitalon and Livagen, which did affect pericentromeric regions in companion experiments, suggesting sequence-specific chromatin targeting rather than nonspecific disruption.
A 2002 microarray study in mouse heart tissue (Anisimov, Bokheler, Khavinson, and Anisimov, Bulletin of Experimental Biology and Medicine) compared Vilon and Epitalon gene expression changes. Both peptides altered distinct, largely non-overlapping gene sets, with limited cross-compound overlap. This compound-specific gene modulation profile is consistent with sequence-selective chromatin binding rather than bulk disruption.
In immunological signaling models, Vilon activates interleukin-2 mRNA synthesis in mouse splenocytes in vitro without exogenous stimulation (Kazakova et al., Bulletin of Experimental Biology and Medicine, 2002). In the 2022 IJMS study by Iannone et al. using differentiated human THP-1 macrophages, Vilon was one of five Khavinson peptides that increased tyrosine phosphorylation of mitogen-activated cytoplasmic kinases and STAT1 phosphorylation. This study, conducted by Italian rather than Russian institutions, provides the only independent external validation of Vilon's intracellular signaling effects.
One mechanistic complexity deserves emphasis: Vilon's chromatin activation and immune stimulation properties, which produce geroprotective effects in standard aging contexts, appear to produce pro-tumorigenic effects in the HER-2/neu transgenic model. This is mechanistically coherent: broad chromatin reactivation and immune cell proliferation stimulation could accelerate tumor growth when an oncogene is already priming cells for division. This context-dependence is important for evaluating the safety profile.
Lezhava et al. (2004) found that Vilon applied to cultured lymphocytes from elderly donors produced four measurable effects: induction of total heterochromatin unrolling, reactivation of ribosomal genes via nucleolus organizer region decondensation, release of genes repressed in facultative heterochromatin, and no effect on pericentromeric structural heterochromatin. The finding of preserved pericentromeric structure with active euchromatin remodeling suggests tissue-specific targeting rather than nonspecific genomic disruption.
The 2006 Lezhava comparison study confirmed the 2004 findings in donors explicitly aged 75 to 88 years, and demonstrated that all three peptides tested (Epitalon, Livagen, Vilon) produced chromatin activation, but that only Epitalon and Livagen affected pericentromeric regions. This differential profile supports sequence specificity in the chromatin interaction.
The 2022 THP-1 macrophage study by Iannone et al., conducted by Italian rather than Russian institutions, found that Vilon increased tyrosine phosphorylation of mitogen-activated cytoplasmic kinases and activated STAT1 signaling in PMA-differentiated THP-1 macrophages. This is the only external replication of Vilon's intracellular signaling effects published to date.
Kazakova et al. found that Vilon activated IL-2 mRNA synthesis in mouse splenocytes in vitro without requiring exogenous mitogenic stimulation. This suggests Vilon can initiate immune gene transcription directly, consistent with the chromatin remodeling mechanism.
The chromatin remodeling finding in human lymphocytes is mechanistically specific and has been reproduced across multiple Lezhava publications. The 2022 external validation from Italian institutions is meaningful. However, none of this work constitutes a clinical trial: no immune function endpoint has been tested in vivo in humans, no infection outcomes, no vaccine response data. The mechanism may be real and relevant; the clinical translation is completely uncharacterized.
The 2000 Khavinson et al. CBA mouse study found that monthly 5-day courses of subcutaneous Vilon (0.1 mcg per animal) from age 6 months until death increased physical activity and endurance, decreased mean body temperature, prolonged mean lifespan, and reduced spontaneous neoplasm incidence compared to saline controls. No unfavorable developmental effects were observed, and estrous function was unaffected.
The 2001 Anisimov et al. comprehensive study in the same CBA mouse model provided biomarker tracking alongside survival data. Vilon treatment maintained immune parameter indices, reduced chromosome aberration frequency in bone marrow, and modestly extended median lifespan. Vilon's lifespan effect was meaningful but smaller than that of Epithalon in the same cohort. The review literature summarizes mean lifespan increases of 20 to 40% for the bioregulator class overall, with Vilon at the lower end of that range.
The CBA mouse data are internally consistent across multiple studies. The limitations are: all data are from female CBA mice, a single strain with specific carcinogenesis susceptibility profiles; all studies originate from the same laboratory; the mouse dose (0.1 mcg per animal, approximately 3 to 5 mcg/kg body weight) is many orders of magnitude below the commercially recommended human protocols of 5,000 to 10,000 mcg per course; and no dose-finding bridge study has been published to justify any specific human dose.
The CBA mouse longevity data are the most quantitatively compelling findings in the Vilon profile. The effect is reproduced across multiple papers, involves hard endpoints (survival, neoplasm incidence), and comes from a group whose internal work also produced the adverse HER-2/neu finding, suggesting they were not simply publishing only favorable results. The complete absence of any human translation study, dose-finding work, or biomarker pilot after four decades is the central unanswered question.
In the 2002 Anisimov et al. HER-2/neu transgenic study, Vilon produced statistically significant adverse effects compared to saline controls: increased mammary tumor incidence (p less than 0.05), shorter mean tumor latency (p less than 0.05), and increased cumulative tumor number (p less than 0.05). In the same experiment, Epitalon produced the opposite result, inhibiting carcinogenesis and reducing maximum tumor size by approximately 33%. HER-2/neu mRNA expression remained elevated in Vilon-treated tumors relative to Epitalon-treated tumors.
The Alimova et al. 2003 study in erbB-2/NEU transgenic mice confirmed the direction of effect: 95% of Vilon-treated mice bore two or more mammary tumors versus 75% of controls.
In contrast, the same research group's 2000 CBA mouse study in non-transgenic animals found that Vilon reduced spontaneous neoplasm incidence over a lifetime. Chinese pharmacology literature (cited in secondary sources) reports dose-dependent in vitro inhibition of LOVO, MKN-45, and QGY7703 human tumor cell lines by Vilon without suppressing normal leukocytes, and in vivo inhibition of H22 hepatoma at 15 to 30 mg/kg.
The HER-2/neu transgenic findings and the standard mouse anticancer findings are mechanistically reconcilable: Vilon's immune activation and chromatin remodeling could suppress carcinogenesis in normal aging contexts while accelerating tumor outgrowth in an oncogene-driven background where immune pathway co-option is already established. The two findings together define a context-dependent oncological profile that has not been fully characterized.
The HER-2/neu pro-tumorigenic finding is published in a peer-reviewed Western journal by the same group responsible for Vilon's geroprotective data. It has not been cited, addressed, or refuted in subsequent Vilon promotion. This is the most important safety finding in the profile and is relevant to anyone with personal or family history of HER-2-positive malignancy. The finding does not establish human cancer risk, but it establishes that pro-tumorigenic effects are biologically possible in a defined genetic context.
Oral Vilon administration to 11-month-old (aged) Wistar rats normalized activity of maltase, alkaline phosphatase, invertase, and dipeptidases in intestinal epithelium and submucosal layers toward levels characteristic of younger animals. In 3-month-old (young) rats, the effects were smaller, consistent with a restorative rather than pharmacologically enhancing mechanism.
The 2002 absorption study found that oral Vilon for 1 month significantly increased glucose and glycine absorption in the medial segment of the small intestine of aged rats. Epithalon produced a similar but regionally distinct effect (proximal and distal segments rather than medial).
These GI findings imply that Vilon is either bioavailable after oral administration (reaching intestinal cells systemically) or acts locally within the gut lumen. No bioavailability study has characterized this. The GI effects are qualitatively different from the immune and chromatin remodeling data and suggest Vilon may influence a broader range of tissue types than its thymic origin implies.
The GI enzyme normalization data are an outlier in the Vilon literature: unusual, understudied, and not referenced in most geroprotection discussions of the compound. The findings are real but their significance for human health is speculative. They raise the interesting question of whether oral Vilon might produce local intestinal gene expression effects without systemic bioavailability, which would have implications for oral dosing strategies.
Khavinson bioregulator peptide.
All published dosing data are from animal studies. Mouse longevity studies used 0.1 mcg per animal subcutaneously. Commercially available human protocols of 5 to 10 mg per course are not grounded in any published dose-finding research and represent a several-orders-of-magnitude extrapolation from animal data. The doseUnit here is mcg; doses shown represent the conservative low end of commercial protocols (100 to 1000 mcg). There is no validated human dose for any indication.
Vilon is most directly compared with Thymalin (unfractionated thymic extract), Thymogen (Glu-Trp, companion dipeptide), and Epithalon (the pineal tetrapeptide most frequently studied alongside it). Thymalin has a larger, though still limited, clinical evidence base in Russian observational practice. Thymogen shares the thymic immunomodulatory focus but uses a different two-amino-acid sequence and emphasizes T-helper differentiation. Epithalon is more widely referenced in Western biohacking contexts due to the telomere hypothesis and has a better preclinical cancer safety profile: in the same HER-2/neu studies where Vilon accelerated carcinogenesis, Epithalon inhibited it. For individuals primarily interested in thymic immune support with the lowest preclinical cancer risk in this compound class, Thymalin or Thymogen may carry less uncertainty than Vilon specifically.
No human pharmacokinetic or formal safety studies have been published for Vilon. No human clinical trial adverse event data exist. No organ-level toxicity has been reported in any published animal study. The compound is composed entirely of amino acids present in normal human metabolism, and the CBA mouse longevity study explicitly concluded that chronic long-term administration caused no unfavorable developmental effects.
The critical published safety concern is the HER-2/neu transgenic mouse data. In a controlled experiment by Anisimov, Khavinson, Provinciali, and colleagues published in the International Journal of Cancer (2002), female HER-2/neu transgenic mice treated with Vilon (1 mcg subcutaneously for 5 days per month from age 2 months) showed statistically significant increases in mammary tumor incidence, shorter tumor latency, and more cumulative tumors compared to saline controls (all p less than 0.05). In the same experiment, Epitalon reduced tumor incidence and size. A second study by Alimova et al. in Advances in Gerontology (2003) in erbB-2/NEU transgenic mice confirmed the pattern: 95% of Vilon-treated mice bore two or more tumors versus 75% of controls.
The mechanism proposed: Vilon's immune-activating effects may promote growth of HER-2-driven tumors that have partially co-opted immune pathways. HER-2/neu transgenic mice carry a constitutively active oncogene in every cell, making this an extreme model that does not directly represent normal human biology. In standard (non-transgenic) CBA mice, Vilon reduced spontaneous neoplasm incidence over a lifetime. The findings are not mutually contradictory, but they establish that pro-tumorigenic effects are biologically possible under specific oncogenic conditions.
Practical safety summary: (1) No safety data in humans, period; (2) Animal data in standard contexts shows no toxicity; (3) HER-2/neu transgenic model shows a statistically significant pro-carcinogenic signal that has not been refuted in subsequent work; (4) Individuals with HER-2-positive malignancy history or strong hereditary risk should treat this finding as a contraindication; (5) Human dose selection is completely empirical; the standard commercial protocol (5 to 10 mg per course) has no published dose-finding basis in any species.
Vilon is the smallest member of the Khavinson bioregulator family, and its profile carries all the strengths and weaknesses of that research program in concentrated form. The chromatin deheterochromatinization finding in human lymphocytes is one of the more directly human-relevant mechanistic demonstrations in the entire bioregulator class: cells from elderly people, treated in vitro, show measurable gene accessibility changes consistent with the proposed mechanism. The 2022 THP-1 macrophage study from Italian institutions adds the first independent external validation that Vilon produces real intracellular signaling effects. The CBA mouse longevity data are internally consistent and span two decades.
The critical problem is the HER-2/neu finding: two peer-reviewed studies from the same group that produced the geroprotective data showed Vilon significantly accelerated mammary carcinogenesis in an oncogene-driven model. This finding is systematically absent from vendor-facing content and popular bioregulator guides. A compound that can activate immune gene expression and cell proliferation broadly will, in an already-oncogenically primed tissue, potentially promote rather than suppress tumor growth. Until this is formally addressed with prospective data, any HER-2-positive malignancy history constitutes a contraindication.
The deeper structural problem with Vilon, shared with Epithalon and Cortagen, is the complete absence of human clinical trials after four decades of animal research. No dose-finding study in humans, no biomarker pilot, no small Phase 1 safety study, exists in the indexed literature. The commercially recommended doses (5 to 10 mg per course) have no published justification. The gap between the mouse dose used in longevity studies (approximately 3 to 5 mcg/kg) and commercial protocols is several orders of magnitude with no dose-escalation rationale. Vilon may be biologically active in humans. But the evidence required to know what dose to use, what to expect, and who should avoid it, does not exist in 2026.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use